Abstract:Abstract Background: Germline mutations in BRCA1, BRCA2 and other genes predispose to high risks of breast cancer. Genetic testing for germline mutations in BRCA1 and BRCA2 has been widely used in women with severe family history of breast or ovarian cancer in many western countries. However, in China, hereditary breast cancer associated genes and their mutation types remain unclear. So far, there's no recommended guidelines for high-risk populations. Next-Generation Sequencing (NGS) technology has been proved to detect all classes of mutations cost-effectively. Here we describe the first study of germline mutations in 196 genes in Chinese breast cancer families using NGS. Methods: Breast cancer patients were consecutively enrolled at diagnosis in our hospital between 2011-2012. Inclusion criteria were as follows: Firstly, breast cancer patients are Shanghai natives; secondly, breast cancer patients aged 35 or younger had at least another family member with any type of cancer or those between 35 and 50 years had ≥2 family members with cancer on same side of family or those above 50 years had ≥3 family members with cancer on same side of family. A total of 196 genes were tested and they included two parts. One hundred and twenty-two genes selected were associated with 54 hereditary cancer syndromes and another 74 genes were cancer susceptibility genes proved by researches published on Pubmed up to 2012. Blood samples were collected and genomic DNA were subjected to targeted capture using the Agilent SureSelect DNA kit and sequencing of exons and flanking regions corresponding to 196 genes using the Illumina HiSeq 2000 platform. All classes of genomic alterations were detected. The study was approved by the Scientific and Ethical Committee of the Cancer Hospital of Fudan University. All participants provided informed consent. Results: Eighty-six breast cancer patients met our inclusion criteria were enrolled in our study. The 86 families totally harbored 456 cancers, mainly including 206(45.2%) breast cancers, 45(9.9%) colorectal carcinomas, 38(8.3%) lung cancers, 36(7.9%) gastric cancers, 28(6.1%) hepatic carcinomas and 17(3.7%) ovarian cancers. A total of 66 germline mutations were detected in 29 genes of 46 probands, including 18 BRCA1 or BRCA2 mutations and one recurrent mutation in each gene, one novel TP53 mutations, one germline mutation in RAD50, PALB2, FANCD2, FANCI, RAD51C, SLX4/FANCP, etc. All of these genes were previously reported in hereditary breast cancer. Of women with germline mutations, the mean age at first primary breast cancer diagnosis was 39.6 y and 10(21.7%) of them had bilateral breast cancer. As for all genomic rearrangements, bioinformatics analysis is in process. Conclusion: This is the first study to report the spectrum of germline mutations in 196 hereditary cancer associated genes in Chinese familial breast cancer patients regardless of cancer types of family members. It will give us a reference for carrying out genetic counseling in Chinese breast cancer families. At the same time, NGS is an effective method to test many genes simultaneously at low cost. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-07-06.

A novel high-throughput assay using mixed genomic DNA for fast screening germline pathogenic variants in breast cancer susceptibility genes

A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

Noninvasive fetal genotyping of single nucleotide variants and linkage analysis for prenatal diagnosis of monogenic disorders

A MALDI-TOF mass spectrometry-based method for detection of copy number variations in BRCA1 and BRCA2 genes

Abstract P2-07-06: Detection of germline mutations in 196 genes in Chinese breast cancer families using targeted capture and next-generation sequencing

Identification and Characterization of Germline Pathogenic Variants Using Matched Tumor-Normal Next-Generation Sequencing in 7363 Pan-Cancer Patients in China

Development and Validation of a New HPV Genotyping Assay Based on Next Generation Sequencing

Application of next-generation sequencing in detection of breast cancer susceptibility genes BRCA1/2,TP53 and PTEN germline mutation

Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions

[Application of Next-Generation Sequencing in Detection of BRCA1/2 and Homologous Recombination Repair Pathway Multi-Genes Germline Mutation and Correlation Analysis].

Comprehensive detection of ctDNA variants at 0.1% allelic frequency using a broad targeted NGS panel for liquid biopsy research.

BRCA Testing by Single-Molecule Molecular Inversion Probes

Multiple Mutation Detection for Risk Assessment in Patients with Breast Cancer by Using Next-Generation Sequencing

A Multiplex PCR-Based Next Generation Sequencing-Panel to Identify Mutations for Targeted Therapy in Breast Cancer Circulating Tumor Cells

Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples

Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study

Automated genotyping of biobank samples by multiplex amplification of insertion/deletion polymorphisms

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study

Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use

The first clinical validation of whole-genome screening on standard trophectoderm biopsies of preimplantation embryos